Relationship between interleukin-17A and isolated coronary ectasia

et al. 2020

BMC Cardiovasc Disord

Background: Coronary artery ectasia (CAE) is an angiographic finding of abnormal coronary dilatation. Inflammation plays a major role in all phases of atherosclerosis. We investigated the relationship between CAE and serum high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy for CAE. Methods: We conducted a prospective analysis of 217 patients with CAE treated at the

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups

et al. 2020

BMC Cardiovasc Disord

“…Dyslipidemia is a well-recognized, major risk factor for atherosclerosis [16,17]. Increased serum lipids, especially LDL-C, will deposit in the arterial wall and gradually form atherosclerotic plaques, which can consequently block the native artery and cause cardiovascular diseases such as coronary heart disease [18]. Increased in ammation is the core process in all stages of atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

et al. 2020

Preprint

Background: Coronary artery ectasia (CAE) is an angiographic finding of abnormal coronary dilatation. The role of inflammation in atherosclerosis is becoming increasingly well known. This study investigated the relationship between CAE and serum levels of high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy for CAE. Methods: We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), and Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015 to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age as follows: CAE-A (age ≤50 years), CAE-B (50 years <age ≤70 years), and CAE-C (age >70). Additionally, there was a normal control (NC) group with normal coronary arteries.Results: All patients received oral rosuvastatin therapy (10 mg, QN quaque nocte) when they were diagnosed with CAE and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The NC group (n = 73, with normal coronary arteries) received regular symptom-relieving treatments and rosuvastatin therapy. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NCs (p<0.01). Logistic regression analysis showed that Hs-CRP (OR=1.782, 95% CI: 1.124-2.014, P=0.021) and IL-6 (OR=1.584, 95% CI: 1.112-1.986, P=0.030) were independent predictors of CAE. The inflammatory markers in the CAE-A group were higher than those in the CAE-B group, which were higher than those in the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which, again, were higher than those in the CAE-C group. Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.

“…Dyslipidemia is a well-recognized, major risk factor for atherosclerosis [13,14]. The increased serum lipids, especially LDL-C, will deposit in the arterial wall, and gradually form atherosclerotic plaques, which can consequently block the native artery and cause cardiovascular diseases such as coronary heart disease [15]. Increased inflammation is the core process in all stages of atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Effects of rosuvastatin treatment on coronary artery ectasia in different patient age groups

et al. 2020

Preprint

Background: This study investigated the relationship between coronary artery ectasia (CAE) and serum levels of high-sensitivity C-reactive protein (Hs-CRP) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy in CAE. Method: We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015, to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age: CAE-A (age ≤50 years); CAE-B (50 years 70). Results: All CAE patients received oral rosuvastatin therapy (10 mg, QN quaque night) and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The control group (NC Group, n = 73, with normal coronary arteries) received regular symptom-relieving treatments. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NC Group. The inflammatory markers in the CAE-A group were higher than in the CAE-B group, which were higher than the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and interleukin-6 levels in the CAE-A group than the CAE-B group, which, again, were higher than the CAE-C group. Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.